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Summary
Background.  —  Coronary  stents  have  evolved  over  time,  from  bare-metal  stents  to  drug-eluting
stents, and  now  to  bioactive  stents.
Aims.  —  We  sought  to  explore  the  immediate  outcome  of  the  titanium-nitride-oxide-coated
bioactive  stent,  Titan2®,  in  real-world  practice,  and  the  incidence  of  major  cardiac  events  at
follow-up.
Methods. —  Consecutive  patients  admitted  for  percutaneous  intervention  for  at  least  one  sig-
niﬁcant (≥  50%)  lesion  in  a  native  coronary  artery  were  treated  with  Titan2® stent  implantation.
The primary  endpoint  was  total  major  adverse  cardiac  events  at  12-month  follow-up.  Secondary
endpoints  included  target  lesion  revascularization  at  12-month  follow-up  and  the  duration  of
dual antiplatelet  therapy.
Results.  —  Among  356  patients  (mean  age  67.4  ±  12.1  years),  77.2%  were  male  and  39.3%  were
treated for  myocardial  infarction  (MI).  A  total  of  546  Titan2® stents  were  implanted  in  420
lesions. Angiographic  and  clinical  procedural  success  was  achieved  in  all  cases.  No  cases  of  in-
hospital major  adverse  cardiac  events  or  acute  stent  thrombosis  were  reported.  Of  335  patients
(94.1%) with  12-month  clinical  follow-up,  four  (1.2%)  died,  MI  occurred  in  ﬁve  (1.5%),  target
lesion revascularization  was  performed  in  17  (5.1%)  and  major  adverse  cardiac  events  occurred
in 24  (7.2%).  One  patient  (0.3%)  suffered  late  stent  thrombosis  during  follow-up,  but  no  cases
of acute  or  subacute  stent  thrombosis  occurred.  Dual  antiplatelet  therapy  continued  beyond
6 months  in  64.5%  of  patients.
Conclusions.  —  In  real-world  practice,  Titan2® stent  implantation  achieves  an  excellent  imme-
diate outcome,  with  a  low  incidence  of  major  adverse  cardiac  events  at  12-month  follow-up.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  sécurité  des  stents  bio-actifs  recouverts  d’oxynitrure  de  titane  a  été  démontrée
pour des  populations  non  sélectionnées  de  type  « vie  réelle  ».
Objectifs.  —  Analyser  d’une  part  les  résultats  immédiats  obtenus  après  implantation  de  stents
coronaires  bio-actifs  Titan2® dans  une  pratique  de  type  « vie  réelle  » et  d’autre  part  les  résultats
cliniques à  savoir  les  Major  Adverse  Cardiac  Events  (MACE)  à  12  mois  de  suivi.
Méthode.  —  Trois  cent  cinquante-six  patients  consécutifs  ont  été  enrôlés  pour  suivre  un  traite-
ment par  angioplastie  percutanée  pour  au  moins  une  lésion  coronaire  signiﬁcative  (50  %).  Toutes
les lésions  ont  été  traitées  par  implantation  d’un  stent  Titan2®.  L’objectif  principal  de  ce  suivi
de cohorte  était  le  taux  de  MACE  à  12  mois.  Les  objectifs  secondaires  comprenaient  le  taux
de revascularisation  de  la  lésion  cible  (TLR)  à  12  mois  et  l’analyse  de  la  durée  du  traitement
antiplaquettaire.
Résultats.  —  L’âge  moyen  était  de  67,4  ±  12,1  ans,  77,2  %  étaient  des  hommes.  Un  total  de
546 Titan2® ont  été  implantés  dans  420  lésions.  Le  succès  angiographique  et  clinique  a  été
atteint pour  toutes  les  procédures.  Aucun  évènement  cardiaque  majeur  intrahospitalier  n’a  été
rapporté  ni  aucune  thrombose  aiguë.  Le  suivi  clinique  à  12  mois  a  été  obtenu  pour  335  (94,1  %)
patients.  Quatre  patients  sont  décédés  (1,2  %)  et  cinq  patients  ont  subi  un  infarctus  (1,5  %).
Une revascularisation  du  vaisseau  cible  a  été  effectuée  chez  17  (5,1  %)  patients.  Vingt-quatre
(7,2 %)  patients  ont  déploré  un  évènement  cardiaque  majeur.  Un  (0,3  %)  patient  a  souffert  d’une
thrombose  tardive,  mais  aucun  cas  de  thrombose  aiguë  ou  sub-aiguë  n’est  arrivé.
Conclusion.  — Dans  une  pratique  de  type  « monde  réel  »,  l’implantation  du  stent  Titan2® est
associé à  d’excellents  résultats  cliniques,  avec  un  taux  d’évènements  cardiaques  majeurs  faible
à 12  mois  de  suivi.
©  2012  Elsevier  Masson  SAS.  Tous  droits  réservés.
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bbreviations
AS bioactive  stents
ES  drug-eluting  stents
AD  left  anterior  descending
Cx  left  circumﬂex
ACE major  adverse  cardiac  event
I myocardial  infarction
CI percutaneous  coronary  intervention
CA right  coronary  artery
IMI  thrombolysis  in  myocardial  infarction
LR  target  lesion  revascularization
ackground
oronary  stent  implantation  has  become  the  standard-of-
are  percutaneous  coronary  intervention  (PCI),  providing
 safer  approach  and  a  better  outcome  than  balloon
ngioplasty  [1,2]. Nevertheless,  since  the  introduction  of
oronary  stents,  in-stent  restenosis  has  been  the  ‘stumbling
lock’  of  this  technology,  resulting  in  repeat  revasculariza-
ion  with  increased  total  costs  [3,4]. The  restenosis  rate
ollowing  bare-metal  stent  implantation  may  approach  30%
n  some  patient  subgroups,  such  as  those  with  diabetes,
mall  coronary  vessels  or  long  lesions  [5,6].
The  introduction  of  drug-eluting  stents  (DES)  has
evolutionized  the  ﬁeld  of  interventional  cardiology,  as  it
as  reduced  the  incidence  of  restenosis  by  50—70%  [7,8].
owever,  recent  worrisome  data  from  registries  and  meta-
nalyses  have  raised  concern  about  the  long-term  safety
f  DES,  highlighting  higher  rates  of  late  and  very  late
tent  thrombosis,  a  potentially  life-threatening  complica-
ion  [9—11].
Stent  technology  has  evolved  recently,  with  the  invention
f  bioactive  stents  (BAS).  The  safety  of  titanium-nitride-
xide-coated  bioactive  stents  (Titan2®)  has  been  established
n  several  reports  from  real-life  unselected  popula-
ions  [12—16]. Interestingly,  some  randomized  trials  have
emonstrated  a  better  outcome  with  BAS  compared  with
aclitaxel-eluting  stents  in  high-risk  patients  with  complex
type  B  and  C)  coronary  lesions  [17,18]  and  in  those  with
yocardial  infarction  (MI)  [19,20].
The  current  registry  was  a  post-approval  registry  per-
ormed  at  the  request  of,  and  under  the  control  of,  the
rench  High  Authority  of  Health  (Haute  Autorité  de  santé,
aint-Denis  La  Plaine,  France).  The  aims  were  to  conﬁrm
he  safety  and  efﬁcacy  of  Titan2® BAS  in  ‘on-label’  indica-
ions  in  real-world  practice  (with  no  exclusion  criteria)  and
stimate  the  duration  and  average  cost  per  patient  of  dual
ntiplatelet  therapy.
ethods
tudy protocolhe  registry  protocol  was  designed  under  the  control  of  the
rench  High  Authority  of  Health,  and  through  collaboration
etween  the  main  investigator,  an  independent  contract
esearch  organization  and  the  manufacturer,  Hexacath.  It
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as  ofﬁcially  validated  and  accepted  on  12  June  2007  by
he  French  High  Authority  of  Health.  No  ﬁnancial  compen-
ation  was  given  to  any  of  the  participating  centres  to
onduct  the  registry,  as  dictated  by  the  French  High  Autho-
ity  of  Health.  The  current  registry  was  executed  under
omplete  data  monitoring  and  surveillance  by  an  indepen-
ent  contract  research  organization  company  (MAPI  NAXIS,
yon,  France).  The  current  registry  was  conducted  accor-
ing  to  the  ‘Standard  Medical  Practice’  (les  bonnes  pratiques
n  épidémiologie  1998  version),  and  law  No.  78-17  dated
6  January  1978  referring  to  private  freedom,  and  follo-
ing  the  article  L.4113-6  of  the  French  Public  National
ealth  Code.
tudy design and population
he  EVIDENCE  Registry  is  a  prospective  multicentre  non-
andomized  observational  registry  performed  in  21  French
edical  centres,  with  the  chief  aim  to  conﬁrm  the  safety
nd  efﬁcacy  of  the  Titan2® BAS  stent  in  real-world  prac-
ice.  Before  the  launch  of  the  registry,  a  scientiﬁc  main
nvestigator  was  nominated  (Prof.  J.-M.  Lablanche,  Cardio-
ogy  Department,  University  Hospital  of  Lille,  France)  and
ssigned  the  task  of  selecting  the  participating  centres,  as
ell  as  validating  the  process  of  data  collection  and  statisti-
al  analysis.  Participating  centres  were  selected  on  the  basis
f  their  high  annual  volume  of  PCI  performance  and  their
apability  to  execute  the  procedures  and  undertake  the  nec-
ssary  follow-up.  Recruitment  of  the  participating  centres
nd  attendant  cardiologists  started  in  June  2007.  Partici-
ating  centres  were  representative  of  the  French  national
gures  regarding  the  volume  of  angioplasties  executed  per
ear.
From  October  2007  to  March  2008,  356  consecu-
ive  patients  with  symptomatic  coronary  artery  disease
menable  for  PCI  were  enrolled,  provided  that  they  were
8  years  or  over,  with  at  least  one  signiﬁcant  coronary  lesion
deﬁned  as  ≥  50%  diameter  stenosis  by  visual  estimation)
n  a  native  coronary  artery.  Treatment  of  more  than  one
essel  was  permissible,  but  only  the  Titan2® stent  was
llowed,  as  dictated  by  the  registry.  Before  inclusion,  a  writ-
en  informed  consent  was  obtained  from  each  patient  after
ull  explanation  of  the  study  protocol,  the  type  of  data  col-
ected,  the  method  of  data  processing  and  the  scope  of  data
ollection.  Collected  data  were  given  a  code  number  for
he  centre  and  another  for  the  patient,  to  ensure  patient
nonymity.
evice
 commercially  available  stainless  steel  tubular  stent  with
he  unique  helicoidal  design  was  used.  The  Titan2® (Hexa-
ath,  Paris,  France)  stent  is  a  thin-strut  (0.07—0.09  mm)
alloon-expandable  stent  made  of  stainless  steel  and  coated
ith  titanium-nitride-oxide,  which  prevents  discharge  of
ickel,  chromium  and  molybdenum  ions.  The  coating  pro-
ess  is  performed  by  plasma-enhanced  vapour  deposition  of
itanium  in  a  pre-speciﬁed  gas  mixture  of  nitrogen  and  oxy-
en  in  a  vacuum  chamber.  Stents  were  available  in  lengths
f  7,  10,  13,  16,  19  and  22  mm  and  in  diameters  of  2.5,  2.75,
.0,  3.5  and  4.0  mm.
d
T
t
o
i
p
a
a
o
f
l
o
N
s
c
S
T
m
S
t
a
w
(
g
i
t
P
o
n
(
s
w
a
‘
a
t
d
s
2
t
d
M
o
e
s
t
w
i
l
S
T
a
tTitanox-coated  stent  in  real-world  practice  
Adjunctive pharmacological therapy
All  included  patients  were  pretreated  with  aspirin  (100  mg
daily).  Oral  clopidogrel  was  initiated  at  a  loading  dose  of
300  mg  before  the  procedure.  The  protocol  gave  no  spe-
ciﬁc  recommendations  regarding  the  duration  of  clopidogrel
maintenance  therapy,  since  one  of  the  objectives  of  this
registry  was  to  investigate  the  routine  medical  practice
concerning  the  duration  of  dual  antiplatelet  therapy  fol-
lowing  PCI  with  BAS.  During  the  procedure,  intravenous
heparin  was  given  to  maintain  an  activated  clotting  time  of
200—300  seconds.  Use  of  periprocedural  glycoprotein  IIb/IIIa
inhibitors  was  left  up  to  the  operator’s  discretion.  The  medi-
cal  treatment  of  coronary  artery  disease  was  optimized
according  to  the  contemporary  guidelines.
Quantitative coronary analysis
Coronary  angiograms  were  obtained  in  multiple  views  after
intracoronary  injection  of  nitrates.  Quantitative  analysis  of
angiographic  data  before  the  procedure  was  performed  in
each  participating  centre  according  to  the  standards  of  care,
using  validated  edge-detection  techniques.  Visual  assess-
ment  included  thrombolysis  in  myocardial  infarction  (TIMI)
ﬂow,  calciﬁcation,  thrombus,  lesion  length,  lesion  classi-
ﬁcation,  dissection  grade  and  aneurysm.  A  contrast-ﬁlled
non-tapered  catheter  was  used  for  calibration.  Interpolated
reference  vessel  diameter,  lesion  length  and  percent  initial
diameter  stenosis  were  measured  before  the  procedure  as
well  as  residual  stenosis  following  stent  implantation.
Angioplasty procedure
Lesions  were  treated  according  to  contemporary  interven-
tional  techniques.  The  investigators  used  similar  materials
and  techniques  throughout  the  study  to  maintain  consis-
tency  and  standardization  of  care.  Predilatation  was  left
to  the  operator’s  discretion.  The  operator  decided  the
appropriate  diameter  to  be  implanted,  aiming  at  a  stent:
vessel  ratio  of  1.1:1  prior  to  stent  placement  (using  nominal
pressure).  Stents  were  expanded  by  adjusting  the  balloon
inﬂation  pressure  to  achieve  an  angiographic  appearance  of
the  expanded  stent  slightly  larger  than  the  reference  ves-
sel  segment.  After  stent  deployment,  post-dilatation  was
allowed.  An  additional  Titan2® stent  could  be  deployed  in
overlap  with  the  ﬁrst  in  case  of  edge  dissection,  incom-
plete  lesion  coverage  or  otherwise  suboptimal  result  (at  the
operator’s  discretion).
Follow-up protocol
The  total  follow-up  period  extended  from  June  2007  to
March  2009.  All  patients  were  observed  during  hospital
stay  for  the  occurrence  of  the  clinical  endpoints  prespec-
iﬁed  by  the  study  protocol  (as  described  below).  Patients
were  prospectively  followed  up  for  a  period  of  12  months
by  means  of  clinic  visits  or  telephone  contacts  by  the
attendant  cardiologists  to  obtain  information  concerning
their  clinical  status,  hospitalization,  invasive  procedures
and  medications.  Follow-up  contacts  were  performed  at
3  and  12  months  following  stent  implantation.  Follow-up
coronary  angiography  was  performed  for  patients  who
o
p
1
a63
eveloped  recurrent  symptoms  during  the  follow-up  period.
he  decision  to  perform  further  revascularization  for  the
arget  lesion  at  follow-up  coronary  angiography  was  based
n  clinical  justiﬁcation  (as  described  below).  A  specialized
ndependent  Contract  Research  Organization  (MAPI  NAXIS)
erformed  additional  telephone  contacts  with  patients  at  3
nd  12  months  following  stent  implantation.  Beforehand,  all
ttendant  cardiologists  had  faxed  a  signed  formal  agreement
f  participation  to  MAPI  NAXIS.  All  patient  data  available
rom  hospital  records  or  attendant  cardiologists  were  col-
ected  in  the  EVIDENCE  Registry  case  report  forms  in  each
f  the  participating  centres,  which  were  provided  by  MAPI
AXIS.  At  the  end  of  follow-up,  all  case  report  forms  were
ent  to  MAPI  NAXIS  and  carefully  reviewed  to  ensure  quality
ontrol  of  the  registered  data.
tudy endpoints and deﬁnitions
he  primary  endpoint  of  the  study  was  the  occurrence  of
ajor  adverse  cardiac  events  (MACE)  at  12-month  follow-up.
econdary  endpoints  included  target  lesion  revasculariza-
ion  (TLR)  at  12-month  follow-up  and  the  duration  and
verage  cost  per  patient  of  dual  antiplatelet  therapy.  MACE
ere  deﬁned  as  a  composite  of  cardiac  death,  non-fatal  MI
including  Q-wave  and  non-Q-wave  MI)  and  TLR.  MI  was  dia-
nosed  by  persistent  ischaemic-type  chest  pain  with  a  rise
n  the  creatine  kinase-MB  fraction  of  more  than  three  times
he  upper  limit  of  normal,  according  to  the  guidelines  for
CI  [21]. Q-wave  MI  was  distinguished  by  the  development
f  new  abnormal  Q  waves,  while  their  absence  identiﬁed
on-Q-wave  MI.  TLR  was  deﬁned  as  a  repeat  intervention
surgical  or  percutaneous)  to  treat  signiﬁcant  luminal  steno-
is  (deﬁned  as  ≥  50%  diameter  stenosis  by  visual  estimation)
ithin  the  stent  or  in  the  5-mm  distal  or  proximal  segments
djacent  to  the  stent.  Revascularization  was  regarded  as
clinically  driven’  if  it  was  motivated  by  angina  symptoms
nd/or  proven  myocardial  ischaemia  in  the  target  vessel
erritory  by  non-invasive  testing.  Angiographic  success  was
eﬁned  as  successful  implantation  of  the  assigned  study
tent  into  the  target  lesion  with  residual  stenosis  less  than
0%  and  TIMI  3  ﬂow  at  the  conclusion  of  the  procedure,  in
he  absence  of  dissection  or  thrombosis.  Clinical  success  was
eﬁned  as  angiographic  success  in  the  absence  of  in-hospital
ACE.  Stent  thrombosis  was  diagnosed  by  the  occurrence
f  acute  coronary  syndrome  with  angiographic  evidence  of
ither  index  vessel  occlusion  or  thrombus  within  the  study
tent,  according  to  the  ‘deﬁnite  category’  deﬁnition  of
he  Academic  Research  Consortium  [22]. Stent  thrombosis
as  classiﬁed  into:  acute  (occurring  within  24  hours  of  the
ndex  procedure),  subacute  (>  24  hours  but  <  30  days)  and
ate  (>  30  days).
tatistical analysis
o  estimate  the  number  of  patients  that  would  give  an
dequately  powered  sample  size,  we  hypothesized  a  MACE
oll  of  11%  at  12-month  follow-up.  This  ﬁgure  was  based
n  prior  studies  employing  the  Titan2® stent  in  unselected
opulations,  that  reported  10.4%  and  10.9%  MACE  at  9  and
2  months’  follow-up,  respectively  [17,23]. Given  the  above
ssumption,  the  number  of  patients  necessary  to  achieve
6 M.  Angioi  et  al.
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Table  2  Angiographic  and  procedural  characteristics  of
the  lesions.
Variable  All  lesions  (n  =  420)
Lesion  type
A  71  (16.9)
B  315  (75.0)
C  34  (8.1)
Lesion  location
LAD 201  (47.9)
LCx 101  (24.0)
RCA 118  (28.1)
Reference  diameter  (mm) 3.0  ±  0.5
Lesion  length  (mm)  11.8  ±  3.6
Initial  stenosis  (%) 83.2  ±  10.7
Stent  diameter  (mm)  3.0  ±  0.4
Stent  length  (mm) 14.4  ±  4.5
Residual  stenosis  (%) 2.4 ±  0.4
Data are presented as mean ± standard deviation or number
(%). LAD: left anterior descending; LCx: left circumﬂex; RCA:
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uch  a  proportion,  with  a  95%  conﬁdence  interval,  was  cal-
ulated  by  means  of  the  following  formula:
 =  p  × (1 −  p) ×
(
1,  96
e
)2
here  p  is  the  proportion  to  estimate  and  e  is  the  absolute
recision  of  estimation.  To  estimate  a  proportion  of  11%,
ith  an  alpha  risk  of  5%  and  an  absolute  precision  of  4%,
 minimum  of  235  patients  needed  to  be  included.  Taking
nto  account  a  proportion  of  patients  lost  to  follow-up  or
xcluded  from  the  analysis  (25—30%),  the  number  of  patients
o  be  enrolled  was  predetermined  to  be  300.
Double  data  entry  was  carried  out.  Source  data  veriﬁ-
ation  was  implemented  to  detect  any  data  discordance.
n  independent  organization  body  (MAPI  NAXIS)  performed
dditional  telephone  contacts  with  patients  at  3  and
2  months  following  stent  implantation  to  collect  data  about
ACE.
Continuous  variables  are  expressed  as  mean  ±  SD,  while
ategorical  variables  are  described  with  their  absolute
nd  relative  (percentage)  frequencies.  Analyses  were  per-
ormed  with  SPSS  version  14.0  statistical  package  (SPSS  Inc.,
hicago,  IL,  USA).
esults
aseline clinical and angiographic
haracteristics
rom  October  2007  to  March  2008,  356  consecutive  patients
ere  enrolled  with  symptomatic  coronary  artery  disease
menable  for  PCI  who  received  at  least  one  Titan2® stent
n  native  coronary  arteries.  Baseline  clinical  characteristics
f  the  study  population  are  shown  in  Table  1.  The  majority  of
Table  1  Baseline  clinical  characteristics  of  the  study
population.
All  patients  (n  =  356)
Age  (years) 67.4  ±  12.1
Men  275  (77.2)
Diabetes  mellitus  65  (18.3)
Dyslipidaemia  223  (62.6)
Current  smoking 136  (38.2)
Myocardial  infarction  140  (39.3)
Q  wave 65  (18.3)
Non-Q  wave 75  (21.1)
Prior  cerebrovascular  stroke 12  (3.4)
Peripheral  arterial  disease  40  (11.2)
TIMI  risk  score  3.1  ±  1.1
Beta  blockera 272  (76.4)
Statina 315  (88.5)
Glycoprotein  IIb/IIIa  inhibitor  36  (10.1)
Data are mean ± standard deviation or number (%). TIMI:
thrombolysis in myocardial infarction.
a On hospital discharge.
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atients  were  males  (77.2%)  and  had  dyslipidaemia  (62.6%),
nd  39.3%  were  treated  for  acute  coronary  syndrome.  Angio-
raphic  and  procedural  characteristics  are  shown  in  Table  2.
ost  of  the  treated  lesions  (75.0%)  were  type  B  according  to
he  American  Heart  Association/American  College  of  Cardio-
ogy  classiﬁcation.
rocedural data
 total  of  546  Titan2® stents  were  implanted  in  420
esions  during  the  index  procedures.  The  mean  stent  dia-
eter  was  3.0  ±  0.4  mm,  while  the  mean  stent  length  was
4.4  ±  4.5  mm  (Table  2).  Stenosis  improved  from  83.2  ±  10.7
o  2.4  ±  0.4%  following  stent  implantation  (Table  2).  Glyco-
rotein  IIb/IIIa  inhibitors  were  used  in  36  patients  (10.1%).
ngiographic  and  clinical  success  was  achieved  in  all  cases
no  cases  of  in-hospital  MACE),  and  no  cases  of  acute  stent
hrombosis  were  reported  during  the  hospital  stay.welve-month follow-up
linical  follow-up  for  12  months  was  completed  in  335
atients  (94.1%).  Table  3  summarizes  the  12-month  clinical
Table  3  Clinical  outcome  at  12-month  follow-up.
Patients  with  12-month
follow-up  (n  =  335)
Cardiac  death  4  (1.2)
Myocardial  infarction  5  (1.5)
TLR  17  (5.1)
Stent  thrombosis  1  (0.3)
MACE 24  (7.2)
Data are number (%). MACE: major adverse cardiac events; TLR:
target lesion revascularization.
Titanox-coated  stent  in  real-world  practice  65
Table  4  Clinical  outcome  of  registries  and  trials  employing  bioactive  stents  at  long-term  follow-up.
Follow-up  (months)  MACE  (%)  Death  (%)  MI  (%)  TLR  (%)
EVIDENCE  Registry 12  7.2  1.2  1.5  5.1
Mosseri  et  al.  [14]  6  7.6  0.7  0.6  5.4
Pori  Registry  [17]  12  10.9  0.5  4.5  5.2
TIBET  Registry  [26]  6  10.3  1.9  1.3  7.1
TITAX  AMI  Trial  [19] 12  10.3  0.5  4.2  9.3
MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularization.
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pfollow-up  data.  During  follow-up,  four  patients  (1.2%)  died
of  a  cardiac  cause,  MI  occurred  in  ﬁve  patients  (1.5%)
(one  ended  in  cardiac  death  and  the  other  underwent  TLR)
and  TLR  was  performed  in  17  patients  (5.1%)  (all  clinically
driven).  MACE  at  12-month  follow-up  occurred  in  24  patients
(7.2%),  i.e.  the  overall  event-free  survival  rate  at  12-month
follow-up  was  92.8%.  The  number  of  patients  who  completed
12-month  follow-up  allowed  the  estimation  of  MACE  (7.2%)
with  an  absolute  precision  of  2.8%  (alpha  risk  of  5%),  that
reasonably  respects  the  prespeciﬁed  requirement  of  the  pro-
tocol.
Only  one  patient  suffered  late  stent  thrombosis  (2  months
and  18  days  after  stent  implantation),  according  to  the  per-
protocol  deﬁnition.  This  was  a  diabetic  woman  aged  85  years
with  acute  coronary  syndrome  treated  for  a  type  C  lesion.
Surprisingly,  this  patient  was  prescribed  clopidogrel  for  only
1  month  after  the  procedure.  No  case  of  acute  or  subacute
stent  thrombosis  occurred  during  follow-up.
Dual  antiplatelet  therapy  was  prescribed  for  1  month
in  55.5%  of  patients,  1—3  months  in  6.8%  and  more  than
3  months  in  37.7%.  Interestingly,  despite  these  initial  pre-
scriptions,  64.5%  of  patients  received  dual  antiplatelet
therapy  for  more  than  6  months.  The  cost  of  the  dual
antiplatelet  therapy  was  estimated  based  on  the  public  price
of  clopidogrel  in  the  French  market  (D55.50  for  28  tablets
of  75  mg  clopidogrel)  at  the  time  of  the  study.  The  average
cost  per  patient  (in  most  centres,  for  stable  patients)  was
estimated  to  be  D55.50  (for  4  weeks)  for  patients  treated
for  stable  angina  or  silent  ischaemia,  and  more  than  D333
(for  >  24  weeks)  for  patients  treated  for  an  acute  coronary
syndrome.
Discussion
The  current  EVIDENCE  Registry  of  the  unrestricted  use  of  the
titanium-nitride-oxide-coated  BAS  in  an  unselected  patient
population  demonstrated  an  excellent  immediate  angio-
graphic  and  clinical  outcome,  with  a  low  incidence  of  MACE
(7.2%)  at  12-month  follow-up.  The  low  incidence  of  MACE
at  12-month  follow-up  is  similar  to  that  reported  for  DES,
and  is  better  than  that  reported  for  bare-metal  stents.  This
conﬁrms  the  favourable  safety/efﬁcacy  proﬁle  of  BAS  in  a
‘real-world’  population  with  no  exclusion  criteria.Titanium-nitride-oxide-coated BAS
Titanium-nitride-oxide-coated  stents  are  a  new  genera-
tion  of  biologically  active  stents.  Titanium  exhibits  a  far
t
D
a
auperior  biocompatibility  than  stainless  steel,  cobalt-
hromium,  gold  or  other  surface-coating  materials,  and
herefore  minimizes  stent-induced  inﬂammation  [24]. Tita-
ium  oxides  have  proven  efﬁcacy  for  inhibiting  platelet
ggregation  and  ﬁbrin  growth  compared  with  carbon  oxides,
hich  are  known  to  be  highly  biocompatible  [25]. Moreover,
etallic  sheaths  coated  with  titanium  nitride  or  titanium
xide  can  promote  endothelial  cell  growth  on  their  surfaces,
uggesting  that  the  use  of  stents  covered  with  these  coatings
ay  accomplish  earlier  complete  endothelialization  [25].
AS outcome in real-world practice
he  EVIDENCE  Registry  has  demonstrated  an  excellent
mmediate  outcome  of  BAS,  with  100%  angiographic  and  cli-
ical  success.  Although  the  study  population  was  a  high-risk
ne  (62.6%  dyslipidaemic,  39.3%  with  acute  coronary  syn-
rome)  with  rather  complex  lesion  characteristics  (83.1%
ype  B  or  C),  no  in-hospital  MACE  were  encountered,  and
nly  one  case  of  ‘deﬁnite’  late  stent  thrombosis  occurred.
he  absence  of  in-hospital  MACE,  considering  the  reaso-
ably  high  prevalence  of  acute  coronary  syndrome  might
e  attributed  to  selection  bias.  This  is  liable  to  occur
ith  observational  registries,  especially  when  the  number
f  patients  enrolled  in  each  individual  centre  is  not  ade-
uately  high.  At  12-month  follow-up,  the  overall  rate  of
ACE,  as  well  as  that  of  its  individual  components  (death,
on-fatal  MI  and  TLR),  was  similar  to  previous  registries
mploying  the  stent  in  unselected  populations  (Table  4)
14,17].  Outcomes  were  also  similar  to  the  use  of  the  stent
n  a  population  of  diabetic  patients  in  the  Titanium-nitride-
xide-coated  stents  multicenter  registry  in  diabetic  patients
TIBET)  (Table  4)  [26], although  it  should  be  noted  that  these
atients  were  generally  more  stable  with  less  complex  lesion
riteria  than  in  the  current  study.
Moreover,  the  fairly  low  incidence  of  MACE  in  the  cur-
ent  registry  was  similar  to  those  reported  in  many  registries
nd  randomized  trials  performed  with  DES  [7,8,27,28]. It
s  well  known  that  most  early  randomized  trials  of  DES
ere  ‘restrained’  by  extensive  lists  of  exclusion  criteria,
.g.  recent  MI,  visible  thrombus  and  bifurcation  lesion.  In
ontrast,  the  EVIDENCE  Registry  was  deliberately  designed
ith  no  exclusion  criteria,  to  reﬂect  ‘real-world  practice’,
nd  involved  a  rather  ‘high-risk’  cohort,  with  quite  com-
lex  lesion  characteristics.  We  can  therefore  speculate  that
he  performance  of  the  BAS  would  have  been  ‘superior’  to
ES  should  it  have  been  employed  in  a  ‘low-risk’  population
nalogous  to  those  of  the  aforementioned  randomized  tri-
ls.  Ultimately,  several  clinical  trials  showed  an  even  better
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utcome  with  BAS  versus  paclitaxel-eluting  stents  in  high-
isk  patients  with  complex  (type  B  and  C)  lesions  [17,18]
nd  in  patients  presenting  with  acute  MI  [19,20].
uration of antiplatelet therapy
ur  data  demonstrate  that  dual  antiplatelet  therapy
as  prescribed  by  interventional  cardiologists  for  more
han  3  months  in  62.3%  of  patients,  most  commonly  for
nly  1  month.  In  reality,  the  proportion  of  patients  pre-
cribed  dual  antiplatelet  therapy  for  short  periods  by  the
nterventional  cardiologists  (62.3%)  matched  the  preva-
ence  of  patients  presenting  with  stable  angina  or  silent
schaemia  (60.7%).  Similarly,  the  proportion  prescribed  dual
ntiplatelet  therapy  for  long  periods  (37.7%)  matched  the
revalence  of  those  presenting  with  an  acute  coronary
yndrome  (39.3%).  In  fact,  the  most  recent  update  of
he  European  Guidelines  do  recommend  continuing  dual
ntiplatelet  therapy  in  patients  presenting  with  acute  coro-
ary  syndrome  for  12  months  unless  there  is  an  excessive  risk
f  bleeding  (class  I-A)  [29].
Interestingly,  however,  despite  the  initial  prescription,
ual  antiplatelet  therapy  was  extended  beyond  6  months
n  64.5%  of  patients.  Considering  that  only  39.3%  of  the
egistry  patients  were  treated  for  acute  coronary  syndrome,
ual  antiplatelet  therapy  was,  therefore,  unduly  prolonged
y  attendant  cardiologists  in  25.2%  of  patients.  Despite  the
lear  recommendations  for  the  optimum  duration  of  dual
ntiplatelet  therapy  after  stent  implantation,  there  is  a  uni-
ersal  tendency  to  ‘keep  on’  this  regimen  for  longer  periods,
oth  in  patients  receiving  bare-metal  stents  and  in  those
eceiving  DES  [30]. However,  a  similar  cohort  (matching
he  EVIDENCE  population)  receiving  DES  would  have  been
appropriately’  prescribed  dual  antiplatelet  therapy  for  at
east  12  months,  for  all  patients.  A  recent  report  from  the
linical  Evaluation  of  the  Xience  V  Everolimus  Eluting  Coro-
ary  Stent  System  in  the  Treatment  of  Patients  with  de
ovo  Native  Coronary  Artery  Lesions  (SPIRIT)  III  trial  compa-
ing  two  DES  demonstrated  that  the  proportion  of  patients
eceiving  dual  antiplatelet  therapy  at  24-month  follow-up
as  59.4%  and  63.9%  for  everolimus-eluting  and  paclitaxel-
luting  stents,  respectively  [31].
linical implications
chievement  of  the  goal  of  reducing  TLR  following  PCI,  with-
ut  the  risk  of  developing  the  unpredictable  life-threatening
hard’  endpoint  of  stent  thrombosis,  and  at  an  almost  similar
ost,  would  be  an  attractive  strategy  in  combating  in-stent
estenosis.  Furthermore,  unlike  DES,  which  need  mainte-
ance  clopidogrel  therapy  for  12  months  (sometimes  for
ven  more  extended  periods),  BAS  require  no  more  than
 month  of  dual  antiplatelet  therapy.  In  the  modern  era  of
scalating  healthcare  costs,  physicians  could  do  both  the
atients  and  the  ‘Healthcare  Systems’  a  great  favour  by
esorting  to  safer  and  less  costly  means  of  maintaining  coro-
ary  patency.  In  this  context,  BAS  may  appear  to  open  a  new
orizon  for  revascularization  of  coronary  atherosclerosis.M.  Angioi  et  al.
tudy limitations
he  EVIDENCE  registry  was  not  randomized,  and  hence
s  liable  to  selection  bias.  Additionally,  it  bears  an  inhe-
ent  limitation  of  any  registry,  namely,  non-blinded  out-
ome  assessment.  Moreover,  although  the  sample  size  was
ormally  calculated,  the  number  of  patients  is  quite  small.
he  rather  high  prevalence  of  patients  presenting  with  an
cute  coronary  syndrome  (39.3%)  is  another  limitation  of  a
egistry  designed,  a  priori,  to  reﬂect  real-world  practice.
urthermore,  longer-term  follow-up  is  still  needed  before
e  can  reach  solid  conclusions  on  the  long-term  safety  of
his  ‘novel’  approach.  Finally,  TLR  was  clinically  driven,  and
his  may  underestimate  the  actual  incidence  of  angiographic
estenosis.  However,  it  would  avoid  unnecessary  interven-
ions  in  borderline  lesions  due  to  the  ‘oculostenotic  reﬂex’
nd  undue  patient  anxiety.
onclusions
AS  implantation  in  ‘real-world’  practice,  in  native  coronary
rteries,  achieves  an  excellent  immediate  clinical  and  angio-
raphic  outcome,  with  a  low  incidence  of  MACE  at  12-month
ollow-up.
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